Clinical trials: Primary Progressive Multiple Sclerosis
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Primary Progressive Multiple Sclerosis, Exercise
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS
Endurance training revealed to be an effective means to increase cardiorespiratory fitness in persons with Multiple Sclerosis (MS), considered relevant to health-related quality of life in this population.
- Conditions
- Primary Progressive Multiple Sclerosis, Exercise, Cardiorespiratory Fitness
- Trial name
- CYPRO (NCT05229861)
- Testing
- HIIT, MCT
- Where
- Switzerland
- Volunteers
- 61 people
- Sponsor
- Klinik Valens
Primary Progressive Multiple Sclerosis
Gray Matter Demyelination in Primary Progressive MS at 7T
Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS.
- Trial name
- NCT04977622
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
- Trial name
- ORATORIO-CP (NCT05974852)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Primary Progressive
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%.
- Trial name
- PRO-COG (NCT03455582)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- 3 sites in France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients
Abstract Introduction: Postural control disorders are the most common motor disorder associated with multiple sclerosis. Objective: The aim of this study is to demonstrate the potential for improvement of postural control, motion…
- Trial name
- NCT03424538
- Testing
- Neurorehabilitation, Physiotherapy
- Where
- Hungary
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting
Exercise Effects in Multiple Sclerosis
A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- NCT05496881
- Testing
- Exercise Group 1, Exercise Group 2, Exercise Group 3
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- University of Regina
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Imaging of Intracerebral Inflammation in MS
In this study we plan to image the compartmentalized inflammation in MS using molecular imaging by positron emission tomography (PET) with a very highly resolutive camera.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- INFLASEP (NCT02305264)
- Testing
- 18F-DPA-714 and 18F-FDG
- Where
- 2 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis
Sunphenon in Progressive Forms of Multiple Sclerosis
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an oral placebo treatment…
- Trial name
- SUPREMES (NCT00799890)
- Testing
- Sunphenon EGCG
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Friedemann Paul
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
- Trial name
- NCT06384976
- Testing
- KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Based on favorable preliminary data from ongoing studies testing the safety and tolerability of a nutrition, exercise and neuromuscular electrical stimulation funded by Direct MS, the investigators are proposing a pilot study…
- Trial name
- NCT01915433
- Testing
- Wahls Paleo Plus, Wahls Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Terry L. Wahls